METROGEL (metronidazole) by Galderma is 12. First approved in 1988.
Drug data last refreshed 5h ago · AI intelligence enriched 2d ago
METROGEL is a topical gel formulation of metronidazole approved for the treatment of rosacea. The mechanism of action in rosacea is unknown, though metronidazole is a well-established antimicrobial and anti-inflammatory agent. Topical application delivers minimal systemic exposure, with plasma concentrations less than 1% of oral dosing.
With LOE approaching and modest Part D penetration, commercial teams should expect declining market opportunity and reduced headcount investment.
12.1 Mechanism of Action The mechanism of action of metronidazole in the treatment of rosacea is unknown. 12.2 Pharmacodynamics The pharmacodynamics of metronidazole in association with the treatment of rosacea are unknown. Cardiac Electrophysiology: The effect of METROGEL on the QTc interval has…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Chlorhexidine and/or Metronidazole Plus FB301 Pre-treatment Trial
A Single-center, Open-label, Study Evaluating Safety and Pharmacokinetics of Single Doses of Zidebactam-Cefepime and Metronidazole Alone or in Combination.
Effectivity and Safety of Metronidazole 1% Cream in Rosacea Therapy
Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)
Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)
Worked on METROGEL at Galderma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moMETROGEL offers limited career upside as a mature, LOE-approaching topical product with minimal Part D volume and declining market presence. Roles on this product are typically defensive in nature, focused on maintaining existing patient base and managing generic transition rather than growth initiatives.